Adjuvant Nivolumab Reduces Risk of Recurrence or Death by 58% in Select Stage IIB or IIC Melanoma
Source: OncLive, October 2022
Adjuvant treatment with nivolumab (Opdivo) resulted in a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) over placebo in patients with completely resected stage IIB or IIC melanoma, meeting the primary end point of the phase 3 CheckMate-76K trial (NCT04099251).
Data presented during the 2022 Society for Melanoma Annual Meeting showed that at the time of a prespecified interim analysis, adjuvant nivolumab resulted in a 58% reduction in the risk of disease recurrence or death compared with placebo (HR, 0.42; 95% CI, 0.30-0.59; P < .0001). The 12-month RFS rate with the immunotherapy was 89% (95% CI, 86%-92%) vs 79% (95% CI, 74%-84%) with placebo.
Notably, the RFS benefit achieved with nivolumab was noted across predefined subsets, such as T category and disease stage. Specifically, in those with stage IIB disease, the 12-month RFS rate achieved with nivolumab was 93% vs 84% with placebo; in the population of patients with stage IIC disease, these rates were 84% vs 72%, respectively.